1. Introduction {#sec1}
===============

During last decades, many efforts have been made to the synthesis and development of supported heterogeneous catalysts that they are often organometallic ([@bib16]; [@bib30]; [@bib59]). Although sometimes it has been observed that homogenous catalysts have been used for the synthesis of a wide range of organic and biologically active compounds ([@bib3]; [@bib20]), but they are minimally recyclable, difficulty to handle and storage, hazardous for environment, and also most of them are expensive, therefore, are not desirable for industrial applications ([@bib22]). As a result, one of the important approaches for overcoming to the above-countered problems is the preparation and application of heterogeneous supported catalysts ([@bib17]; [@bib58]). Heterogeneous supported catalysts generally have numerous benefits such as good catalytic performance, recyclability, environment safety, high stability, being cheap, and simple handling ([@bib36]). So synthesis and characterization of heterogeneous supported catalysts and their applications in the synthesis of organic and heterocyclic compounds have recently been attracted the interest of chemists and industrialism ([@bib2]). Aliphatic amines such as piperidine or piperazine due to the presence of delocalized electrons on nitrogen are known as organic base, which are used as conventional active catalyst for the synthesis of organic compounds ([@bib25]; [@bib28]), but they have some disadvantages such as what mentioned above for homogeneous catalysts along with they are mostly soluble in organic solvents and their separation from homogeneous reaction mixtures require neutralization by acidic conditions, which lead to worthless ammonium salt ([@bib52]; [@bib54]). Harmful effects of acidic work-ups can be removed by immobilization of aliphatic amines for example piperazine onto solid supports to obtain heterogeneous catalysts ([@bib24]). To profit from this technology, to date, various clean materials such as graphene (oxide) sheets ([@bib14]; [@bib31]), silica or mesoporous silica ([@bib50]; [@bib55]), Fe~3~O~4~ nanoparticles ([@bib40]), and dendrimer ([@bib51]), have been using as support for preparation of new heterogeneous base catalysts to overcome the problems related to the homogeneous base catalysts.

Tungsten is an important element in chemistry and compounds containing tungsten have wide range of applications not only in chemical laboratories but also in various fields of industries such as catalysts ([@bib33]), optical fibers ([@bib39]), and sensors ([@bib56]), and electrochromic applications ([@bib35]). Meanwhile, tungstate supported catalysts for the synthesis of organic compounds have also been recently applied successfully ([@bib19]; [@bib26], [@bib27]).

Chromene and its derivatives are very important *O*-containing heterocyclic compounds in medicinal chemistry. They have shown so many biological activities including reducing the risk of cardiovascular diseases ([@bib6]), anti-allergic ([@bib10]), anti-microbial ([@bib10]), analgesic ([@bib10]), anti-parkinsonian ([@bib7]), anti-human immune deficiency virus (HIV) ([@bib7]), antibacterial ([@bib34]), anti-tumor ([@bib7]) anti-diabetic ([@bib12]) and anti-inflammatory ([@bib12]). Also, some of them have recognized as non-nucleoside reverse transcriptase inhibitor ([@bib11]), and act in the role of an enzyme that can catalyze chemical reactions ([@bib13]). Taking a brief look at [Fig. 1](#fig1){ref-type="fig"} which shows some significant biological active compounds containing chromene framework, can more disclosed the highly importance of this family of heterocyclic compounds ([@bib6]; [@bib11]; [@bib12]; [@bib13]; [@bib34]).Fig. 1Selected significant biologically active compounds containing a chromene framework.Fig. 1

In regard to the importance of chromene and its derivatives ([@bib41], [@bib42]; [@bib44], [@bib45]) and also the significant role of supported heterogeneous catalysts in chemical syntheses and industries ([@bib1]; [@bib8]; [@bib9]; [@bib43]), herein we wish to report a nano-sized novel heterogeneous supported Brönsted base as an efficient catalyst which was successfully applied to synthesis of new 4*H*-chromene derivatives. We called this newly prepared nanocatalyst bis(3-(piperazine-1-yl)propyl) tungstate (BPPT) that was prepared in an alternative two-step route from sodium tungstate (**1**), 1-bromo-3-chloro-propane (**2**), and piperazine (**4**) ([Scheme 1](#sch1){ref-type="fig"}).Scheme 1Alternative two-step route to the preparation of BPPT.Scheme 1

In continuous of our research on the synthesis of biological active compounds ([@bib18]; [@bib46]), heterogeneous catalysts ([@bib15]; [@bib49]), and a wide range of organic and heterocyclic compounds ([@bib5], [@bib4]), in this work we wish to report preparation and characterization of BPPT, for the first time, and its performance as a nano-sized heterogeneous catalyst in a one-pot three-component combinatorial reaction via a green procedure. It found that BPPT as a heterogeneous Brønsted base can successfully catalyze Knoevenagel condensation, Michael addition and intramolecular cyclization reaction between methyl cyanoacetate (**5**), a wide range of aryl aldehydes **6**, and dimedone (**7**) to afford 4-aryl substituted 4*H*-chromene derivatives **8** in good to excellent yields ([Scheme 2](#sch2){ref-type="fig"}).Scheme 2BPPT-catalyzed green synthesis of 4*H*-chromene derivatives.Scheme 2

2. Results and discussion {#sec2}
=========================

With reference to green chemistry aspects, it is very important that chemical reactions have been run under green conditions. Hence the use of eco-friendly catalysts and solvents are inevitable. Also, industrially and economic point of view it is very important that applied catalysts in chemical reactions to be highly efficient and recyclable. Accordingly, so many attempts have been taken place so far by chemists to the preparation of green, highly efficient and recyclable catalysts and their applications in organic syntheses ([@bib16]; [@bib30]; [@bib59]). Based on above, herein we wish to report a novel, highly efficient and eco-friendly nano-catalyst and its first application in the synthesis of 4*H*-chromene derivatives as highly efficient, and recyclable basic catalyst. By a brief looking at [Scheme 1](#sch1){ref-type="fig"}, it is leveled that newly prepared catalyst which was called BPPT was synthesized in an alternative two-step route from sodium tungstate **1**, 1-bromo-3-chloropropane **2** and piperazine **4**. As can be seen from [Scheme 1](#sch1){ref-type="fig"}, in the first step, bis(3-chloropropyl)tungstate **3** is formed from the reaction between sodium tungstate **1** and 1-bromo-3-chloropropane **2**, then in the second step, 1-bromo-3-chloropropane 2 is treated with piperazine 4 to afford bis(3-(piperazine-1-yl)propyl) tungstate nanoparticles (BPPT NPs). It is noteworthy to consider that the reaction procedure is clean and easy. BPPT NPs was characterized by FT-IR spectra, scanning electron microscopy (SEM), transmission electron microscopy (TEM) and atomic absorption.

2.1. Characterization and application of catalyst {#sec2.1}
-------------------------------------------------

[Fig. 2](#fig2){ref-type="fig"} shows mixing FT-IR spectra of the anhydrous sodium tungstate 1, 1-bromo-3-chloropropane 2, piperazine 4, and BPPT NPs. By a brief looking at the spectrum of BPPT NPs and its comparison with the spectra of starting materials, it is obviously revealed that both 1-bromo-3-chloropropane and piperazine have joined to tungstate core. For instance, the spectrum of BPPT NPs shows significant peaks of tungstate group (appeared at 3462 and 836 cm^−1^), important peaks of the propyl group appeared at 2927 cm^−1^ (CH stretch) and 1448 cm^−1^ (CH bend), and distinguished peaks of piperazine appeared at 3173 cm^−1^ and 2706 cm^−1^. Also, the investigation of the catalyst by atomic absorption spectroscopy showed the existence of tungsten in catalyst structure that is in agreement with appeared peaks of tungstate group in FT-IR spectroscopy.Fig. 2Comparable FT-IR spectra of anhydrous sodium tungstate, 1-bromo-3-chloropropane, piperazine, and BPPT NPs.Fig. 2

The scanning electron microscope (SEM) image of as-prepared BPPT NPs shows the bis(3-(piperazine-1-yl)propyl) tungstate nanoparticles have a diameter of around 30 nm ([Fig. 3](#fig3){ref-type="fig"}). Furthermore, the transmission electron microscopy (TEM) image of BPPT NPs was taken to more investigate of BPPT NPs morphology ([Fig. 4](#fig4){ref-type="fig"}). The TEM image of BPPT NPs clearly disclosed the BPPT NPs have a diameter size of about 30 nm.Fig. 3The SEM image of BPPT NPs.Fig. 3Fig. 4The TEM image of BPPT NPs.Fig. 4

Also, to support the stability of BPPT NPs at high temperatures, thermogravimetric (TGA) analysis was carried out ([Fig. 5](#fig5){ref-type="fig"}). From the obtained TGA curve, it was revealed that weight percent remains constant till 100 °C. Therefore, it is concluded that the BPPT NPs is stable in temperatures below 100 °C.Fig. 5The TGA analysis of BPPT NPs.Fig. 5

After characterization of the catalyst, with respect to the importance of using novel green and recyclable heterogeneous catalyst in chemical synthesis, herein, we decided to use and investigate the effectiveness of BPPT NPs in the synthesis of 4*H*-chromene derivatives. In continues of our research studies on the synthesis and application of nanocatalysts in organic syntheses ([@bib15]; [@bib29]; [@bib50]), we found that BPPT NPs can act as a potent, green and recyclable catalyst in an alternative two-step reactions that is Knoevenagel condensation and Michael reaction between methyl cyanoacetate (**5**), aryl aldehydes **6** and dimedone (**7**) to afford chromene derivatives **8** in good to excellent yields ([Scheme 2](#sch2){ref-type="fig"}).

In this protocol, it was found that BPPT NPs has significant advantages including being eco-friendly, recyclability, high thermal stability, and also high efficiency.

Before start reaction runs, it was necessary to find optimum conditions for reaction progress. For this purpose, compound **8d** was selected as a model. Loading model reaction in various solvents including dichloromethane, chloroform, toluene, water, DMF, acetonitrile, THF, methanol, and ethanol disclosed that reaction progress was faster in ethanol than others and caused to obtain the product with the highest yield. Next, the effect of temperature on reaction progress was assessed, and it was found that 70 °C is the best temperature to achieve the product with the highest yield. In the next step, other same catalysts were applied to the model reaction and compared with BPPT NPs. From obtained results which are summarized in [Table 1](#tbl1){ref-type="table"}, it is understood that BPPT NPs is the most effective catalyst in the synthesis of the target compound.Table 1Effect of different catalysts on a model reaction.[a](#tbl1fna){ref-type="table-fn"}Table 1EntryCatalystTimeYield[b](#tbl1fnb){ref-type="table-fn"}1FeCl~3~.6H~2~O90682Y(NO~3~).6H~2~O80753CuSO~4~.5H~2~O80654*p*-TSA80705Na~2~HPO~4~60816K~2~CO~3~60827Na~2~WO~4~.2H~2~O60848Piperidine60809BPPT NPs4095[^1][^2]

In the next step, the effect of catalyst amount on the model reaction was examined that obtained results are summarized in [Table 2](#tbl2){ref-type="table"}. By a closer looking at [Table 2](#tbl2){ref-type="table"}, it is found that the use of the catalyst in this reaction is inevitable and the best amount of required catalyst which leads to obtaining target product with the highest yield is 5 mol%.Table 2Optimization of catalyst amount for the model reaction.[a](#tbltbl2fna){ref-type="table-fn"}Table 2EntryCatalyst (mol%)Time (min)Yield[b](#tbl2fnb){ref-type="table-fn"} (%)1\-\--90Trace216050326088434090544093654095764095874093[^3][^4]

After achieving optimal conditions, in order to examine the generality of the protocol, the reaction was loaded with methyl cyanoacetate (**5**), a wide range of aryl aldehydes **6** and dimedone (**7**) in the presence of 5 mol% BPPT NPs as basic catalyst and the results were summarized in [Table 3](#tbl3){ref-type="table"} ([@bib23]; [@bib37]; [@bib48]; [@bib53]; [@bib57]).Table 3Synthesis of 4*H*-chromene derivatives using BPPT NPs.[a](#tbl3fna){ref-type="table-fn"}Table 3Compound[b](#tbl3fnb){ref-type="table-fn"}ArTime (min)/(lit.)Yield[c](#tbl3fnc){ref-type="table-fn"} (%)/(lit.)M.P. (lit.)8a4-(2-morpholinoethoxy)-C~6~H~4~6087174--175[d](#tbl3fnd){ref-type="table-fn"}8b4-(4-morpholino)-C~6~H~4~6085188--189[d](#tbl3fnd){ref-type="table-fn"}8c4-(4-piperidin-1-yl)-C~6~H~4~6080170--173[d](#tbl3fnd){ref-type="table-fn"}8d4-(4-chlorobenzyloxy)-C~6~H~4~4095158--160[d](#tbl3fnd){ref-type="table-fn"}8e3-(4-chlorobenzyloxy)-C~6~H~4~4592159--161[d](#tbl3fnd){ref-type="table-fn"}8f4-(4-bromobenzyloxy)-C~6~H~4~4095158--161[d](#tbl3fnd){ref-type="table-fn"}8g3-(4-bromobenzyloxy)-C~6~H~4~5093164--167[d](#tbl3fnd){ref-type="table-fn"}8h4-F-C~6~H~4~4090143--145[d](#tbl3fnd){ref-type="table-fn"}8i3-Br-C~6~H~4~4588174--176[d](#tbl3fnd){ref-type="table-fn"}8j2-Br-C~6~H~4~4591197--200[d](#tbl3fnd){ref-type="table-fn"}8kC~6~H~5~40/1088/92145-147 (144--146) ([@bib53])8l4-Cl-C~6~H~4~40/2091/91167-169 (170--171) ([@bib23])8m2-Cl-C~6~H~4~40/6091/70196-199 (198--200) ([@bib57])8n3-Cl-C~6~H~4~40/6087/86178-179 (178--179) ([@bib37])8°4-NO~2~-C~6~H~4~30/1894/92181-183 (187--188) ([@bib23])8p3-NO~2~-C~6~H~4~30/2093/80190-192 (191--192) ([@bib48])8q2-NO~2~-C~6~H~4~30/6095/87187-189 (188--189) ([@bib37])8r4-CH~3~-C~6~H~4~40/1091/90178-181 (172) ([@bib53])[^5][^6][^7][^8]Fig. 6The chemical structures of synthesized compounds.Fig. 6

For confirmation of obtained products **8**, their chemical structures were characterized by FT-IR, ^1^H NMR, ^13^C NMR spectroscopies, and also elemental analyses (Figs. S1--S30, supplementary materials). For example, the ^1^H NMR spectrum of **8d** (Fig. S10) indicates an identifiable singlet at 7.56 ppm related to NH~2~ group, multiple peaks around 7.46 are correlated with four protons of the aromatic ring, two doublets appeared in 7.07 and 6.86 ppm are corresponded for four protons of the other 1,4-substituted phenyl ring. Three singlets appeared at 5.03, 4.49, and 3.52 ppm are corresponded for two protons of OCH~2~ group, one proton of methine group, and three protons of OCH~3~ group respectively. The four doublets in chemical shifts of 2.55, 2.46, 2.27, and 2.07, each for one proton, are related to four diastereotopic protons of cyclohexenone fragment. Also, the six protons related to two methyls groups (2×CH~3~) are appeared at 1.05 and 0.90 ppm as two singlets. ^13^CNMR spectrum of **8d** (Fig. S11) also shows 21 distinct resonances in agreement with the proposed structure. Furthermore, FT-IR spectrum of **8d** (Fig. S12) clearly disclosed the bonds correlated to NH~2~ and carbonyl groups at 3431, 3315, 1688 and 1666 cm^−1^ respectively compatible with proposed structures.

2.2. Recyclability study of BPPT NPs {#sec2.2}
------------------------------------

Despite being effective and requiring a small amount of catalyst, the capability of catalyst to reuse is the other advantage of BPPT NPs. In this content, we wish to examine the recyclability of catalyst on model reaction. For this purpose model reaction was loaded using 5 mol% of fresh, once, twice, three-, four- and five-time used BPPT NPs. For reusing catalyst in another cycle, it should be separated from the reaction mixture by filtering and washing with THF, drying at 80 °C for 1 h, and then can reuse in further cycles. The results showed that BPPT NPs is able to reuse in further cycles (up to five times) besides its first use without a remarkable miss of activity ([Fig. 7](#fig7){ref-type="fig"}).Fig. 7Recyclability studies of BPPT NPs on model reaction.Fig. 7

In an additional investigation, the FT-IR spectra of the catalyst before and after use as an appropriate comprehensive study for recycled catalyst were compared ([Fig. 8](#fig8){ref-type="fig"}). The FT-IR spectrum of the catalyst after use ([Fig. 8](#fig8){ref-type="fig"}b) showed no significant changes than the specrum of the catalyst before use ([Fig. 8](#fig8){ref-type="fig"}a). This reveals that the catalyst is durable, and remains constant during the reaction. Therefore, it can reuse in further runs without significant loss in its activity and is capable to catalyze the reaction after each run successfully.Fig. 8The FT-IR spectra of the catalyst (a) befor and (b) after use.Fig. 8

2.3. Investigation of reaction mechanism {#sec2.3}
----------------------------------------

A proposed mechanism for the BPPT NPs catalyzed the synthesis of 4*H*-chromene derivatives has shown in [Scheme 3](#sch3){ref-type="fig"}. As can be seen from the mechanism, 4*H*-chromene **8** is obtained through a multi-step route including Knoevenagel condensation, Michael addition reaction and intramolecular cyclization from reaction between methyl cyanoacetate **5**, aryl aldehyde **6** and dimedone **7** in the presence of catalytic amount of BPPT NPs. By a closer look at [Scheme 3](#sch3){ref-type="fig"}, it is revealed that in all steps BPPT NPs act as activator and accelerate reaction progress via its [Brønsted](http://en.wikipedia.org/wiki/Br%C3%B8nsted%E2%80%93Lowry_acid%E2%80%93base_theory){#intref0010} base virtue. In first step, BPPT NPs activate methyl cyanoacetate **5** for nucleophilic attack to aldehyde **6** and leads to formation of int. **9**. Next, dehydration of int. **9** in the presence of BPPT NPs gives Knoevenagel intermediate **10**. On the other hand, BPPT NPs activate dimedone **7** to nucleophilic attack to Knoevenagel intermediate **10 (**Michael addition reaction). By this reaction, int. **11** is formed. Subsequent intramolecular cyclization of int. **11** in the presence of BPPT NPs gives int. **12**. In the final step, product **8** is obtained by imine-enamine tautomerization of int. **12**.Scheme 3Proposed mechanism for the BPPT NPs-catalyzed synthesis of 4*H*-chromene derivatives.Scheme 3

2.4. Molecular docking studies {#sec2.4}
------------------------------

The containing of alkylamine side chain in BPPT chemical structure and considering the structures of drugs that inhibit acetylcholinesterase enzyme such as donepezil, and rivastigmine (used for the treatment of Alzheimer, Parkinson, and Autism), and also other potent acetylcholinesterase inhibitors that have contained piperidine or piperazine side chains in their structures ([@bib38]; [@bib47]), we decided to study molecular docking for BPPT, and compare the results with the Donepezil as reference drug to treatment of Alzheimer ([Fig. 9](#fig9){ref-type="fig"}). As can be seen from [Fig. 9](#fig9){ref-type="fig"}a, BPPT interacted with donepezil binding site of AChE as great as donepezil. Also in [Fig. 9](#fig9){ref-type="fig"}b, it is clearer that BPPT has an excellent matching in width and length with donepezil and exactly overlap with donepezil structure to interact with AChE enzyme.Fig. 9(a) Molecular interactions of BPPT and Donepezil (reference drug) with AChE enzyme. (b) The great structural matching of BPPT with donepezil to interact with AChE enzyme.Fig. 9

The investigation of molecular interaction of BPPT with AChE revealed that there are five significant interactions that are two π-cation interactions between NH~2~^+^ groups with TRP86 and TRP286, two H-bond interactions between oxygen with TYR124, and GLU202 with NH~2~^+^ group, and finally a salt-bridge interaction between NH~2~^+^ group with GLU202 ([Fig. 10](#fig10){ref-type="fig"}).Fig. 10The most significant interactions between BPPT and AChE enzyme.Fig. 10

In addition, docking results indicated Glide XP G-score (a parameter corresponding ligand-protein stability in which more negative scores are related to better fillers and imply less steric hindrance and signifies that the ligand can fill the poses of the protein very well) of BPPT (-10.323) is close to donepezil (-16.144) ([Table 4](#tbl4){ref-type="table"}).Table 4*In silico* prediction of pharmacokinetic/pharmacodynamic characteristics of BPPT to inhibition of AChE versus Donepezil.Table 4CompoundRule of FiveQplogBB[a](#tbltbl4fna){ref-type="table-fn"}QPlogKhsa[b](#tbltbl4fnb){ref-type="table-fn"}Human Oral Absorption[c](#tbltbl4fnc){ref-type="table-fn"}QPlogHERG[d](#tbltbl4fnd){ref-type="table-fn"}XP G-score[e](#tbltbl4fne){ref-type="table-fn"}Donepezil[f](#tbltbl4fnf){ref-type="table-fn"}00.0630.597100 %-6.528-16.144BPPT0-0.526-0.74137.9 %-7.405-10.323[^9][^10][^11][^12][^13][^14]

Therefore, docking studies represented that BPPT has a great affinity with donepezil structure to bind and block the sites of the AChE enzyme.

2.5. ADMETox prediction {#sec2.5}
-----------------------

In another supplement survey, to investigate the biological properties of BPPT and the prediction that can it be a good candidate as AChE inhibitor?, *In silico* ADMETox prediction study was performed, compared with donepezil, and the results were summarized in [Table 4](#tbl4){ref-type="table"}. ADMETox prediction revealed that BPPT has no variation from Lipinski\'s rule of five as of donepezil. It can permeate into the blood-brain barrier (BBB) as good as donepezil. Both BPPT and donepezil are capable of binding well to human serum albumin, but their quantitative human oral absorptions are not identical. As predicted results showed, quantitative human oral absorptions of BPPT is not as good as donepezil. As well as, predicted IC~50~ for the blockage of HERG K^+^ channels in heart for both BPPT and donepezil was not in acceptable range, therefore they could be the HERG K^+^ channels blockers. On the other hand, HERG K^+^ channels blocking of donepezil has previously been proved and considered as one of the known side-effects of the Donepezil. It can induce "torsades de point" which is characterized as marked QT prolongation in electrocardiogram, and may result in cardiac syncope ([@bib32]). This side-effect is known to be related to the inhibition of hERG protein in cardiomyocytes ([@bib32]). This fact can further confirm the accuracy of our prediction tool. Overall, ADMETox prediction depicted that BPPT can be a good candidate for AChE inhibitors and can be a lead compound for further discoveries of anti-Alzheimer drugs.

3. Experimental {#sec3}
===============

All used chemicals were supplied from Merck or Sigma-Aldrich as mercantile chemical companies. An Electrothermal-9100 apparatus was applied to record melting points and all of them are uncorrected. Elemental analyses of compounds were carried out by a Heracus CHN-O-Rapid analyzer. An FT-IR Magna 550 spectrophotometer (Nicolet) using KBr as a carrier was applied to record FT-IR spectra. All FT-NMRs were taken by an FT-NMR Bruker 300 MHz spectrometer. The progress of the reactions was monitored by thin-layer chromatography (Silica TLC F~254~ plates, eluent: ethyl acetate/*n-*hexane v*/*v = 1:1). Scanning electron microscopy (SEM) evaluations of the nano-catalyst were performed on a JEOL JEM 3010 instrument operating at an accelerating voltage of 300 kV. Transmission electron microscopy (TEM) investigations of the nano-catalyst were performed on a JEOL JEM 3010 instrument operating at an accelerating voltage of 300 kV. Thermogravimetric (TG) measurements were carried out using a thermal gravimetric analyzer (BAHR, STA 503) from room temperature to 1100 °C in air at a heating rate of 10 °C min^−1^. Acetylcholinesterase (AChE) structure was extracted from the Protein Data Bank (PDB) database which was co-crystalized with Donepezil as an antagonist. The protein structure was prepared in pH = 7.4 ± 1 using the Maestro interface of Schrodinger Suite. Het groups and waters with less than 3 hydrogen bonds to non-waters were removed and hydrogen bonds were reassigned using PROPKA. A final minimization of the structure to an RMSD of less than 0.3 Å was performed to remove atom clashes and reduce steric hindrance. The binding site of Donepezil with AChE was used as a pattern to create grid-files for computational molecular docking.

The structure of BPPT was drawn in Chemdraw software and optimized using Ligprep with Optimized Potential for Liquid Simulations 3 (OPLS3) force-field and the 3D-optimized form was generated in pH = 7.4 ± 1. Computational molecular docking was performed using Glide module with extra precision (XP) method ([@bib21]) for both BPPT and Donepezil as a reference compound. Ligand sampling was set to flexible (including ring conformations and nitrogen inversions and Epik state penalties were incorporated to docking scores. A post docking minimization was applied by employing strain correction terms. Maestro interface was used as the molecular visualization of all figures.

Absorption, Distribution, Metabolism, Excretion, and Toxicity of the BPPT, was assessed using QikProp. Blood-Brain Barrier (BBB) permeability, percent of human oral absorption, prediction of binding to human serum albumin and IC~50~ for the blockage of HERG K^+^ channels in heart, and also ligand-protein stability score for BPPT were compared with donepezil as a reference drug.

3.1. Preparation of BPPT NPs {#sec3.1}
----------------------------

Sodium tungstate dihydrate (7 g) was firstly dried by a vacuum oven under 120 °C for 6 h. Next, anhydrous sodium tungstate **1** (20 mmol, 5.88 g) was gradually added to a stirred 250 mL round bottom flask containing 1-bromo-3-chloropropane **2** (40 mmol, 6.28 g) in 50 mL *n*-hexane at room temperature during 15 min. After 48 h, the reaction mixture was filtrate to separate bis(3-chloropropyl)tungstate **3**. Obtained solid material **3** was washed with distilled water to remove side product, sodium bromide salt. 15 mL distilled water in five times (3 mL in each time) was used until filtrate become free of bromide ion. To identification of bromide ion silver nitrate solution (0.05 M) was applied. Solid material **3** was dried in vacuum oven at 100 °C for 5 h. In the next step, to a 250 mL round bottom flask containing 60 mL toluene equipped with reflux condenser, connected to a water bowl by a hoses interface, solid **3** (16 mmol, 6.4 g) was added, then piperazine **4** (32 mmol, 2.8 g) was gradually added to the flask during 15 min. When the addition of piperazine was completed, it was allowed to the reaction mixture to stir for 0.5 h in room temperature and then 48 h under reflux conditions. Afterward, the reaction mixture was filtrated to obtain BPPT. Finally, after drying catalyst at 100 °C for 5 h, 28 g BPPT was obtained and was characterized by FT-IR spectroscopy, TEM, and SEM microscopes and also TGA measurement.

3.2. General procedure to the synthesis of methyl 2-amino-7,7-dimethyl-5-oxo-4-aryl substituted-5,6,7,8-tetrahydro-4H-chromene-3-carboxylate {#sec3.2}
--------------------------------------------------------------------------------------------------------------------------------------------

To a stirred round bottom flask containing ethanol (12 mL) along with catalytically amounts of BPPT (0.50 g, 5 mol%), appropriate aryl aldehyde (2.0 mmol), and methyl cyanoacetate (2.5 mmol, 0.25 g) was added. After stirring reaction mixture for 1 h at room temperature, dimedone (2.0 mmol, 0.280 g) was added, and it was allowed to the mixture\'s temperature to rise at 70 °C. The reaction progress was monitored by TLC (ethyl acetate/*n-*hexane v*/*v = 1:1). After passing the appropriate time, indicated in [Table 2](#tbl2){ref-type="table"}, the boiling ethanol (50 mL) was added to the reaction mixture till crude products completely dissolved, then the mixture was filtered to separate catalyst. The catalyst was washed with boiling ethanol, dried at 100 °C for 2 h and reused in another cycle. The filtrate was evaporated to obtain the crude product. The crystalline pure product was obtained from the crystallization of crude product in boiling ethanol. The chemical structures of novel crystalline pure products were confirmed by FT-IR, ^1^H NMR, ^13^C NMR spectroscopies, elemental analyses (C, H, N) and for known compounds via comparison of their melting points with the reported ones.

3.3. Spectroscopic data of novel synthesized products {#sec3.3}
-----------------------------------------------------

Methyl 2-amino-7,7-dimethyl-4-(4-(2-morpholinoethoxy)phenyl)-5-oxo-5,6,7,8-tetrahydro-4*H*-chromene-3-carboxylate **(8a):** Snow white powder, m.p: 174--175 °C; FT-IR (KBr) (ῡ~max~, cm^−1^): 3387, 3284, 3060, 2958, 2865, 2801, 1693, 1693, 1669, 1534, 1509, 1365, 1295, 1251, 1201, 1146, 1037, 846, 541. ^1^H NMR (DMSO-*d*~*6*~, 300 MHz) *δ* (ppm): 7.55 (2H, s, NH~2~), 7.04 (2H, d, *J* = 9 Hz, CH~Ar~), 6.78 (2H, d, *J* = 9 Hz, CH~Ar~), 4.47 (1H, s, CH), 4.02 (2H, t, *J* = 6 Hz, OCH~2~), 3.59 (4H, t, *J* = 6 Hz, CH~2~OCH~2~), 3.52 (3H, s, OCH~3~), 2.69 (2H, t, *J* = 6 Hz, NCH~2~), 2.52 (4H, t, *J* = 6 Hz, CH~2~NCH~2~), 2.49 (2H, m, CH~2~), 2.27 (1H, d, *J* = 15 Hz, CH), 2.06 (1H, d, *J* = 15 Hz, CH), 1.05 (3H, s, CH~3~), 0.90 (3H, s, CH~3~). ^13^C NMR (DMSO-*d*~*6*~, 75 MHz) *δ* (ppm): 196.3, 168.8, 162.3, 159.7, 157.0, 138.9, 128.8, 116.3, 114.2, 78.3, 66.5, 65.4, 57.5, 54.0, 50.9, 50.4, 32.6, 32.3, 29.1, 26.9. Anal. calcd for C~25~H~32~N~2~O~6~: C, 65.77; H, 7.07; N, 6.14; Found: C, 65.81; H, 7.12; N, 6.09%.

Methyl 2-amino-7,7-dimethyl-4-(4-morpholinophenyl)-5-oxo-5,6,7,8-tetrahydro-4*H*-chrome-ne-3-carboxylate **(8b):** Light yellow crystals, m.p: 188--189 °C; FT-IR (KBr) (ῡ~max~, cm^−1^): 3390, 3280, 3058, 2957, 2870, 2822, 1690, 1652, 1609, 1529, 1439, 1364, 1287, 1156, 1120, 1104, 921. ^1^H NMR (DMSO-*d*~*6*~, 300 MHz) *δ* (ppm): 7.52 (2H, s, NH~2~), 6.99 (2H, d, *J* = 9Hz, CH~Ar~), 6.79 (2H, d, *J* = 9 Hz, CH~Ar~), 4.44 (1H, s, CH), 3.71 (4H, brs, CH~2~OCH~2~), 3.36 (3H, s, OCH~3~), 3.04 (4H, brs, CH~2~NCH~2~), 2.52 (2H, m, CH~2~), 2.27 (1H, d, *J* = 15 Hz, CH), 2.07 (1H, d, *J* = 15 Hz, CH), 1.05 (3H, s, CH~3~), 0.91 (3H, s, CH~3~). ^13^C NMR (DMSO-*d*~*6*~, 75 MHz) *δ* (ppm): 196.3, 168.9, 162.3, 159.7, 149.5, 137.6, 128.4, 116.4, 115.1, 78.5, 66.6, 50.9, 50.5, 49.0, 32.5, 32.3, 29.1, 27.0. Anal. calcd for C~23~H~28~N~2~O~5~: C, 66.97; H, 6.84; N, 6.79; Found: C, 67.05; H, 6.79; N, 6.83%.

Methyl 2-amino-7,7-dimethyl-5-oxo-4-(4-(piperidin-1-yl)phenyl)-5,6,7,8-tetrahydro-4*H*-chr-omene-3-carboxylate **(8c):** Golden rod crystals, m.p: 170--173 °C; FT-IR (KBr) (ῡ~max~, cm^−1^): 3412, 3301, 3085, 2933, 2853, 2792, 1695, 1656, 1612, 1513, 1437, 1367, 1288, 1204, 1164, 1036, 840, 497. ^1^H NMR (DMSO-*d*~*6*~, 300 MHz) *δ* (ppm): 7.52 (2H, s, NH~2~), 6.98 (2H, d, *J* = 9 Hz, CH~Ar~), 6.77 (2H, d, *J* = 9 Hz, CH~Ar~), 4.44 (1H, s, CH), 3.53 (3H, s, OCH~3~), 3.04 (4H, t, *J* = 6 Hz, CH~2~NCH~2~), 2.54 (1H, d, *J* = 18 Hz, CH), 2.54 (1H, d, *J* = 18 Hz, CH), 2.27 (1H, d, *J* = 15 Hz, CH), 2.08 (1H, d, *J* = 15 Hz, CH), 1.59 (4H, m, 2×CH~2~), 1.51 (2H, m, CH~2~), 1.05 (3H, s, CH~3~), 0.92 (3H, s, CH~3~). ^13^C NMR (DMSO-*d*~*6*~, 75 MHz) *δ* (ppm): 196.3, 168.9, 162.2, 159.7, 150.3, 136.9, 128.3, 116.5, 115.8, 78.5, 50.9, 50.5, 50.1, 32.4, 32.3, 29.1, 26.9, 25.9, 24.3. Anal. calcd for C24H30N2O4: C, 70.22; H, 7.37; N, 6.82; Found: C, 70.27; H, 7.31; N, 6.85%.

Methyl 2-amino-4-(4-((4-chlorobenzyl)oxy)phenyl)-7,7-dimethyl-5-oxo-5,6,7,8-tetrahydro-4H-chromene-3-carboxylate **(8d):** White crystals, m.p: 158--160 °C; FT-IR (KBr) (ῡ~max~, cm^−1^): 3431, 3315, 3060, 2953, 2929, 2869, 1688, 1666, 1606, 1506, 1368, 1300, 1233, 1200, 1163, 1014, 875, 814, 559, 539. ^1^H NMR (DMSO-*d*~*6*~, 300 MHz) *δ* (ppm): 7.56 (2H, s, NH~2~), 7.46 (4H, m, CH~Ar~), 7.07 (2H, d, *J* = 6 Hz, CH~Ar~), 6.86 (2H, d, *J* = 6 Hz, CH~Ar~), 5.03 (2H, s, OCH~2~), 4.49 (1H, s, CH), 3.52 (3H, s, OCH~3~), 2.55 (1H, d, *J* = 18 Hz, CH), 2.46 (1H, d, *J* = 18 Hz, CH), 2.27 (1H, d, *J* = 15 Hz, CH), 2.07 (1H, d, *J* = 15 Hz, CH), 1.05 (3H, s, CH~3~), 0.90 (3H, s, CH~3~). ^13^C NMR (DMSO-*d*~*6*~, 75 MHz) *δ* (ppm): 196.2, 168.8, 162.4, 159.7, 156.8, 139.3, 136.7, 132.8, 129.9, 128.9, 128.8, 116.3, 114.5, 78.3, 68.7, 50.9, 50.4, 32.7, 32.3, 29.1, 26.9. Anal. calcd for C~26~H~26~ClNO~5~: C, 66.74; H, 5.60; N, 2.99; Found: C, 66.80; H, 5.55; N, 3.07%.

Methyl 2-amino-4-(3-((4-chlorobenzyl)oxy)phenyl)-7,7-dimethyl-5-oxo-5,6,7,8-tetrahydro-4H-chromene-3-carboxylate (**8e**): Snow white crystals, m.p: 159--161 °C; FT-IR (KBr) (ῡ~max~, cm^−1^): 3416, 3302, 3064, 2950, 2868, 1691, 1655, 1612, 1517, 1439, 1370, 1291, 1249, 1202, 1171, 1028, 802, 689, 491. ^1^H NMR (DMSO-*d*~*6*~, 300 MHz) *δ* (ppm): 7.60 (2H, s, NH~2~), 7.47 (4H, m, CH~Ar~), 7.14 (1H, t, *J* = 9 Hz, CH~Ar~), 6.79--6.76 (2H, m, CH~Ar~), 6.74 (1H, s, CH~Ar~), 5.05 (2H, dd, ^3^*J* = 15 Hz, ^4^*J* = 6 Hz, OCH~2~), 4.52 (1H, s, CH), 3.52 (3H, s, OCH~3~), 2.55 (1H, d, *J* = 18 Hz, CH), 2.45 (1H, d, *J* = 18 Hz, CH), 2.27 (1H, d, *J* = 15 Hz, CH), 2.07 (1H, d, *J* = 18 Hz, CH), 1.04 (3H, s, CH~3~), 0.89 (3H,s,CH~3~). ^13^C NMR (DMSO-*d*~*6*~, 75 MHz) *δ* (ppm): 196.2, 168.7, 162.7, 159.8, 158.2, 148.4, 136.6, 132.8, 129.9, 129.3, 128.9, 120.5, 116.0, 114.8, 112.2, 77.8, 68.7, 50.9, 50.4, 33.4, 32.3, 29.0, 26.9. Anal. calcd for C~26~H~26~ClNO~5~: C, 66.74; H, 5.60; N, 2.99; Found: C, 66.79; H, 5.63; N, 3.05%.

Methyl 2-amino-4-(4-((4-bromobenzyl)oxy)phenyl)-7,7-dimethyl-5-oxo-5,6,7,8-tetrahydro-4H-chromene-3-carboxylate (**8f**): Snow white crystals, m.p: 158--161 °C; FT-IR (KBr) (ῡ~max~, cm^−1^): 3434, 3315, 3049, 2954, 2926, 1688, 1666, 1606, 1506, 1436, 1369, 1300, 1234, 1199, 1163, 1012, 873, 810, 555. ^1^H NMR (DMSO-*d*~*6*~, 300 MHz) *δ* (ppm): 7.61 (2H, s, NH~2~), 7.57 (2H, d, *J* = 6 Hz, CH~Ar~), 7.40 (2H, d, *J* = 6 Hz, CH~Ar~), 7.06 (2H, d, *J* = 9 Hz, CH~Ar~), 6.86 (2H, d, *J* = 9 Hz, CH~Ar~), 5.01 (2H, s, OCH~2~), 4.48 (1H, s, CH), 3.52 (3H, s, OCH~3~), 2.55 (1H, d, *J* = 15 Hz, CH), 2.45 (1H, d, *J* = 15 Hz, CH), 2.27 (1H, d, *J* = 15 Hz, CH), 2.07 (1H, d, *J* = 15 Hz, CH), 1.05 (3H, s, CH~3~), 0.90 (3H,s,CH~3~). ^13^C NMR (DMSO-*d*~*6*~, 75 MHz) *δ* (ppm): 196.3, 168.8, 162.4, 159.7, 156.8, 139.3, 137.1, 131.8, 130.2, 128.9, 121.3, 116.3, 114.5, 78.2, 68.7, 51.0, 50.4, 32.6, 32.3, 29.1, 26.9. Anal. calcd for C~26~H~26~BrNO~5~: C, 60.95; H, 5.11; N, 2.73; Found: C, 60.99; H, 5.06; N, 2.80%.

Methyl 2-amino-4-(3-((4-bromobenzyl)oxy)phenyl)-7,7-dimethyl-5-oxo-5,6,7,8-tetrahydro-4H-chromene-3-carboxylate (**8g**): Snow white crystals, m.p: 164--167 °C; FT-IR (KBr) (ῡ~max~, cm^−1^): 3415, 3300, 3050, 2948, 2867, 1690, 1655, 1595, 1517, 1439, 1370, 1290, 1249, 1202, 1172, 1027, 802, 778, 689, 495. ^1^H NMR (DMSO-*d*~*6*~, 300 MHz) *δ* (ppm): 7.60 (2H, d, *J* = 9 Hz, CH~Ar~), 7.58 (2H, s, NH~2~), 7.41 (2H, d, *J* = 9 Hz, CH~Ar~), 7.14 (1H, t, *J* = 9 Hz, CH~Ar~), 6.79--6.75 (2H, m, CH~Ar~), 6.74 (1H, s, CH~Ar~), 5.03 (2H, dd, ^3^*J* = 18 Hz, ^4^*J* = 6 Hz, OCH~2~), 4.52 (1H, s, CH), 3.51 (3H, s, OCH~3~), 2.55 (1H, d, *J* = 18 Hz, CH), 2.45 (1H, d, *J* = 18 Hz, CH), 2.27 (1H, d, *J* = 15 Hz, CH), 2.06 (1H, d, *J* = 15 Hz, CH), 1.04 (3H, s, CH~3~), 0.88 (3H, s, CH~3~). ^13^C NMR (DMSO-*d*~*6*~, 75 MHz) *δ* (ppm): 196.2, 168.7, 162.7, 159.8, 158.2, 148.3, 137.1, 131.8, 130.2, 129.3, 121.3, 120.5, 116.0, 114.8, 112.3, 77.8, 68.7, 51.0, 50.4, 33.4, 32.3, 29.0, 26.9. Anal. calcd for C~26~H~26~BrNO~5~: C, 60.95; H, 5.11; N, 2.73; Found: C, 61.01; H, 5.05; N, 2.81%.

Methyl 2-amino-4-(4-fluorophenyl)-7,7-dimethyl-5-oxo-5,6,7,8-tetrahydro-4H-chromene-3-carboxylate (**8h**): White powder, m.p: 143--145 °C; FT-IR (KBr) (ῡ~max~, cm^−1^): 3464, 3309, 3040, 2967, 2935, 1694, 1657, 1526, 1506, 1436, 1365, 1295, 1224, 1198, 1163, 1036, 849, 769, 645, 542. ^1^H NMR (DMSO-*d*~*6*~, 300 MHz) *δ* (ppm): 7.37 (2H, s, NH~2~), 6.91 (2H, d, *J* = 9 Hz, CH~Ar~), 6.79 (2H, t, *J* = 9 Hz, CH~Ar~), 4.28 (1H, s, CH), 3.27 (3H, s, OCH~3~), 2.31 (1H, d, *J* = 18 Hz, CH), 2.22 (1H, d, *J* = 18 Hz, CH), 2.03 (1H, d, *J* = 15 Hz, CH), 1.83 (1H, d, *J* = 15 Hz, CH), 0.80 (3H, s, CH~3~), 0.65 (3H, s, CH~3~). ^13^C NMR (DMSO-*d*~*6*~, 75 MHz) *δ* (ppm): 196.2, 168.7, 162.6, 159.7, 142.9, 129.7 (d, *J* = 7.5 Hz), 115.9, 115.1, 114.8, 77.8, 51.0, 50.3, 33.0, 32.3, 29.0, 26.9. Anal. calcd for C~19~H~20~FNO~4~: C, 66.08; H, 5.84; N, 4.06; Found: C, 66.13; H, 5.78; N, 4.10%.

Methyl 2-amino-4-(3-bromophenyl)-7,7-dimethyl-5-oxo-5,6,7,8-tetrahydro-4H-chromene-3-carboxylate (**8i**): White crystals, m.p: 174--176 °C; FT-IR (KBr) (ῡ~max~, cm^−1^): 3399, 3298, 3043, 2960, 2875, 1696, 1656, 1535, 1437, 1365, 1286, 1200, 1163, 1072, 1034, 771, 695, 514. ^1^H NMR (DMSO-*d*~*6*~, 300 MHz) *δ* (ppm): 7.66 (2H, s, NH~2~), 7.33--7.30 (1H, m, CH~Ar~), 7.28 (1H, s, CH~Ar~), 7.21 (1H, t, *J* = 9 Hz, CH~Ar~), 7.17--7.14 (1H, m, CH~Ar~), 4.51 (1H, s, CH), 3.53 (3H, s, OCH~3~), 2.57 (1H, d, *J* = 15 Hz, CH), 2.50 (1H, d, *J* = 15 Hz, CH), 2.30 (1H, d, *J* = 15 Hz, CH), 2.10 (1H, d, *J* = 15 Hz, CH), 1.05 (3H, s, CH~3~), 0.90 (3H, s, CH~3~). ^13^C NMR (DMSO-*d*~*6*~, 75 MHz) *δ* (ppm): 196.3, 168.5, 163.0, 159.7, 149.5, 130.7, 130.6, 129.2, 127.1, 121.5, 115.4, 77.3, 51.0, 50.3, 33.6, 32.3, 29.0, 26.8. Anal. calcd for C~19~H~20~BrNO~4~: C, 56.17; H, 4.96; N, 3.45; Found: C, 56.10; H, 4.88; N, 3.51%.

Methyl 2-amino-4-(2-bromophenyl)-7,7-dimethyl-5-oxo-5,6,7,8-tetrahydro-4H-chromene-3-carboxylate (**8j**): White crystals, m.p: 197--200 °C; FT-IR (KBr) (ῡ~max~, cm^−1^): 3424, 3313, 3045, 2966, 2924, 1693, 1651, 1610, 1516, 1437, 1362, 1289, 1202, 1082, 1037, 828, 761, 739, 506. ^1^H NMR (DMSO-*d*~*6*~, 300 MHz) *δ* (ppm): 7.67 (2H, s, NH~2~), 7.45 (1H, dd, ^3^*J* = 9 Hz, ^4^*J* = 3 Hz, CH~Ar~), 7.25 (1H, dt, ^3^*J* = 9 Hz, ^4^*J* = 3 Hz, CH~Ar~), 7.16 (1H, dd, ^3^*J* = 9 Hz, ^4^*J* = 3 Hz, CH~Ar~), 7.02 (1H, dt, ^3^*J* = 9 Hz, ^4^*J* = 3 Hz, CH~Ar~), 4.86 (1H, s, CH), 3.47 (3H, s, OCH~3~), 2.59 (1H, d, *J* = 18 Hz, CH), 2.44 (1H, d, *J* = 18 Hz, CH), 2.26 (1H, d, *J* = 15 Hz, CH), 2.02 (1H, d, *J* = 15 Hz, CH), 1.05 (3H, s, CH~3~), 0.91 (3H, s, CH~3~). ^13^C NMR (DMSO-*d*~*6*~, 75 MHz) *δ* (ppm): 196.0, 168.9, 162.6, 159.6, 145.3, 133.0, 131.7, 128.0, 127.7, 123.7, 115.0, 77.2, 50.7, 50.5, 34.3, 32.2, 29.1, 26.9. Anal. calcd for C~19~H~20~BrNO~4~: C, 56.17; H, 4.96; N, 3.45; Found: C, 56.23; H, 4.89; N, 3.49%.

4. Conclusions {#sec4}
==============

In conclusion, we found BPPT NPs as an efficient, and eco-friendly heterogeneous recyclable organometallic Brønsted base which can catalyze successfully multi-step reaction including Knoevenagel condensation, Michael addition reaction and intramolecular cyclization between methyl cyanoacetate, aryl aldehydes, and dimedone to yield 4*H*-chromene derivatives in good to excellent yields. Therefore, BPPT NPs can be applied as a catalyst in reactions in which needs basic catalyst or media. Hence, it can attract many interests and find many applications in organic syntheses in future. This methodology not only produces the products with excellent yields in short reaction times but also keeps away from some disadvantages such as catalyst handling and cost, pollution and safety. Also, easy work-up, recyclability and thermal stability of catalyst are other advantages of BPPT NPs. In addition, molecular modeling and ADMETox prediction results showed that BPPT can be considered as a potent AChE inhibitor, and can be a lead compound to further discovery of anti-Alzheimer drugs.
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[^1]: Reaction conditions: catalyst (5 mol%), methyl cyanoacetate (1.25 mmol), 4-((4-chlorobenzyl)oxy)benzaldehyde (1 mmol), dimedone (1 mmol), EtOH (8 mL), 70 °C.

[^2]: Refers to isolated yields.

[^3]: Reaction conditions: methyl cyanoacetate (1.25 mmol), 4-((4-chlorobenzyl)oxy)benzaldehyde (1 mmol), dimedone (1 mmol), EtOH (8 mL), 70 °C.

[^4]: Refers to isolated yields.

[^5]: Reaction conditions: methyl cyanoacetate (1.25 mmol), aryl aldehyde (1 mmol), dimedone (1 mmol), nanocatalyst (5 mol%), EtOH (8 mL), 70 °C.

[^6]: The chemical structures of compounds are listed in [Fig. 6](#fig6){ref-type="fig"}.

[^7]: Refers to isolated yields.

[^8]: Novel compounds.

[^9]: Predicted blood-brain barrier coefficient (Recommended Range: -3 -- 1.2).

[^10]: Prediction of binding to human serum albumin (Recommended. Range: -1.5 -- 1.5).

[^11]: Predicted quantitative human oral absorption on 0--100% scale; \>80% is high and \<25% is poor.

[^12]: Predicted IC~50~ for the blockage of HERG K^+^ channels in the heart (concern below -5).

[^13]: A parameter corresponding ligand-protein stability that more negatives values imply that the poses of the target protein (binding sites) are filled by the ligand very good.

[^14]: Reference drug.
